Trial Profile
Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications Giant lymph node hyperplasia; Kaposi's sarcoma; Non-Hodgkin's lymphoma; Primary-Effusion-Lymphoma
- Focus Adverse reactions
- 06 May 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 04 Sep 2014 New trial record